Sana Biotechnology (SANA) reported Tuesday "positive" initial results from a study that transplanted islet cells into a person with type 1 diabetes without the use of immunosuppression.
Sana shares were rising 225% in recent after-hours trading.
The study showed that the company's hypoimmune, or HIP, technology enabled the transplanted islet cells to avoid rejection and produce insulin without immunosuppression, the company said.
"Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin," Sana said.
The study didn't identify any safety issues, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。